The Experts below are selected from a list of 270 Experts worldwide ranked by ideXlab platform

A Pavie - One of the best experts on this subject based on the ideXlab platform.

  • predictive risk factors for primary graft failure requiring temporary extra corporeal membrane oxygenation support after Cardiac Transplantation in adults
    European Journal of Cardio-Thoracic Surgery, 2011
    Co-Authors: Cosimo Dalessandro, Jeanlouis Golmard, Eleodoro Barreda, M Laali, Ralouka Makris, Charlesedouard Luyt, Pascal Leprince, A Pavie
    Abstract:

    Objective:Primarygraftfailure(PGF)isa majorriskfactorfordeathafterheartTransplantation.Weinvestigatedthepredictiveriskfactorsfor severe PGF that require extra-corporeal membrane oxygenation (ECMO) circulatory support after Cardiac Transplantation. Methods: Between January 2003 and December 2008, 402 adult patients underwent isolated Cardiac Transplantation at our institution. PGF was defined as the need for ECMO support in the immediate postoperative period. Thirty-three recipient and 37 donor variables were analyzed for the risk of PGF occurrence. Results: PGF occurred in 91 (23%) patients. Predictive risk factors for PGF occurrence were, in the recipient, being aged >60 years (odds ratio (OR) 2.11, p = 0.01) and preoperative mechanical circulatory support (MCS) (OR 2.65, p = 0.01); in the donor, they were mean norepinephrine dose (OR 2.02,p < 0.01), trauma as the cause of death(OR 2.45,p < 0.01), left-ventricle ejection fraction (LVEF) <55% (OR 2.72, p = 0.02), and the ischemic time (OR 1.01, p < 0.01). Weaning and discharge rates after ECMO support for PGF were, respectively, 60% (55/91 patients) and 46% (42/91 patients).The absence of PGF was correlated with improved long-termsurvival: 78% at 1 year and 71% at 5 years without PGF versus 39% at 1 year and 34% at 5 years with PGF (p < 0.01). Surviving patients treated with ECMO for PGF have similar conditional 1-year survival rates as non-PGF patients: 93% at 3 years and 91% at 5 years without PGF versus 93% at 3 years and 84% at 5 years with PGF (p = 0.46, NS). Conclusions: Occurrence of PGF is a multifactorial event that depends on both donor and recipient profiles. ECMO support is a reliable treatment for severe PGF;furthermore,survivingpatients treated with ECMO have the same 1-year conditional survival ratesas patients not havingsuffered a PGF. # 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

  • extra corporeal membrane oxygenation temporary support for early graft failure after Cardiac Transplantation
    European Journal of Cardio-Thoracic Surgery, 2009
    Co-Authors: Cosimo Dalessandro, Jeanlouis Golmard, Charlesedouard Luyt, A Pavie, Stephane Aubert, Beltran Levy G Praschker, I Gandjbakhch, Pascal Leprince
    Abstract:

    Objective: Early graft failure (EGF) is a major risk for death after heart Transplantation. We studied the impact of an extra-corporeal membrane oxygenation (ECMO) temporary support on the operative mortality and the mean-term survival after EGF. Materials and methods: Between January 2000 and December 2006, 394 patients underwent orthotopic heart Transplantation at our institution. EGF was observed in 90 (23%) patients. Fifty-four patients (14%) were treated with ECMO support, eight (2%) with other assisting devices, and 28 (7%) received maximal inotropic drug support only. Results: The overall mortality was 21% (83 patients). EGF was a major risk for death: 13% (35 patients) without EGF versus 58% (49 patients) with EGF, p < 0001. Among patients supported with ECMO, 36 (67%) were weaned from the assisting device and 27 (50%) were discharged from the hospital. Overall survival was 73% at 1 year and 66% at 5 years. Absence of EGF improved long-term survival: 78% at 1 year and70% at5 years withoutEGFversus 37%at 1 year and35% at5 years withEGF. Patientstreated withECMO havethe same1-yearconditional survival as patients not having suffered EGF: 94% at 3 years. Conclusions: ECMO support is a reliable therapeutic option in severe EGF after Cardiac Transplantation; furthermore, patients treated with ECMO have the same 1-year conditional survival as patients not having suffered EGF. # 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Pascal Leprince - One of the best experts on this subject based on the ideXlab platform.

  • predictive risk factors for primary graft failure requiring temporary extra corporeal membrane oxygenation support after Cardiac Transplantation in adults
    European Journal of Cardio-Thoracic Surgery, 2011
    Co-Authors: Cosimo Dalessandro, Jeanlouis Golmard, Eleodoro Barreda, M Laali, Ralouka Makris, Charlesedouard Luyt, Pascal Leprince, A Pavie
    Abstract:

    Objective:Primarygraftfailure(PGF)isa majorriskfactorfordeathafterheartTransplantation.Weinvestigatedthepredictiveriskfactorsfor severe PGF that require extra-corporeal membrane oxygenation (ECMO) circulatory support after Cardiac Transplantation. Methods: Between January 2003 and December 2008, 402 adult patients underwent isolated Cardiac Transplantation at our institution. PGF was defined as the need for ECMO support in the immediate postoperative period. Thirty-three recipient and 37 donor variables were analyzed for the risk of PGF occurrence. Results: PGF occurred in 91 (23%) patients. Predictive risk factors for PGF occurrence were, in the recipient, being aged >60 years (odds ratio (OR) 2.11, p = 0.01) and preoperative mechanical circulatory support (MCS) (OR 2.65, p = 0.01); in the donor, they were mean norepinephrine dose (OR 2.02,p < 0.01), trauma as the cause of death(OR 2.45,p < 0.01), left-ventricle ejection fraction (LVEF) <55% (OR 2.72, p = 0.02), and the ischemic time (OR 1.01, p < 0.01). Weaning and discharge rates after ECMO support for PGF were, respectively, 60% (55/91 patients) and 46% (42/91 patients).The absence of PGF was correlated with improved long-termsurvival: 78% at 1 year and 71% at 5 years without PGF versus 39% at 1 year and 34% at 5 years with PGF (p < 0.01). Surviving patients treated with ECMO for PGF have similar conditional 1-year survival rates as non-PGF patients: 93% at 3 years and 91% at 5 years without PGF versus 93% at 3 years and 84% at 5 years with PGF (p = 0.46, NS). Conclusions: Occurrence of PGF is a multifactorial event that depends on both donor and recipient profiles. ECMO support is a reliable treatment for severe PGF;furthermore,survivingpatients treated with ECMO have the same 1-year conditional survival ratesas patients not havingsuffered a PGF. # 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

  • extra corporeal membrane oxygenation temporary support for early graft failure after Cardiac Transplantation
    European Journal of Cardio-Thoracic Surgery, 2009
    Co-Authors: Cosimo Dalessandro, Jeanlouis Golmard, Charlesedouard Luyt, A Pavie, Stephane Aubert, Beltran Levy G Praschker, I Gandjbakhch, Pascal Leprince
    Abstract:

    Objective: Early graft failure (EGF) is a major risk for death after heart Transplantation. We studied the impact of an extra-corporeal membrane oxygenation (ECMO) temporary support on the operative mortality and the mean-term survival after EGF. Materials and methods: Between January 2000 and December 2006, 394 patients underwent orthotopic heart Transplantation at our institution. EGF was observed in 90 (23%) patients. Fifty-four patients (14%) were treated with ECMO support, eight (2%) with other assisting devices, and 28 (7%) received maximal inotropic drug support only. Results: The overall mortality was 21% (83 patients). EGF was a major risk for death: 13% (35 patients) without EGF versus 58% (49 patients) with EGF, p < 0001. Among patients supported with ECMO, 36 (67%) were weaned from the assisting device and 27 (50%) were discharged from the hospital. Overall survival was 73% at 1 year and 66% at 5 years. Absence of EGF improved long-term survival: 78% at 1 year and70% at5 years withoutEGFversus 37%at 1 year and35% at5 years withEGF. Patientstreated withECMO havethe same1-yearconditional survival as patients not having suffered EGF: 94% at 3 years. Conclusions: ECMO support is a reliable therapeutic option in severe EGF after Cardiac Transplantation; furthermore, patients treated with ECMO have the same 1-year conditional survival as patients not having suffered EGF. # 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Cosimo Dalessandro - One of the best experts on this subject based on the ideXlab platform.

  • predictive risk factors for primary graft failure requiring temporary extra corporeal membrane oxygenation support after Cardiac Transplantation in adults
    European Journal of Cardio-Thoracic Surgery, 2011
    Co-Authors: Cosimo Dalessandro, Jeanlouis Golmard, Eleodoro Barreda, M Laali, Ralouka Makris, Charlesedouard Luyt, Pascal Leprince, A Pavie
    Abstract:

    Objective:Primarygraftfailure(PGF)isa majorriskfactorfordeathafterheartTransplantation.Weinvestigatedthepredictiveriskfactorsfor severe PGF that require extra-corporeal membrane oxygenation (ECMO) circulatory support after Cardiac Transplantation. Methods: Between January 2003 and December 2008, 402 adult patients underwent isolated Cardiac Transplantation at our institution. PGF was defined as the need for ECMO support in the immediate postoperative period. Thirty-three recipient and 37 donor variables were analyzed for the risk of PGF occurrence. Results: PGF occurred in 91 (23%) patients. Predictive risk factors for PGF occurrence were, in the recipient, being aged >60 years (odds ratio (OR) 2.11, p = 0.01) and preoperative mechanical circulatory support (MCS) (OR 2.65, p = 0.01); in the donor, they were mean norepinephrine dose (OR 2.02,p < 0.01), trauma as the cause of death(OR 2.45,p < 0.01), left-ventricle ejection fraction (LVEF) <55% (OR 2.72, p = 0.02), and the ischemic time (OR 1.01, p < 0.01). Weaning and discharge rates after ECMO support for PGF were, respectively, 60% (55/91 patients) and 46% (42/91 patients).The absence of PGF was correlated with improved long-termsurvival: 78% at 1 year and 71% at 5 years without PGF versus 39% at 1 year and 34% at 5 years with PGF (p < 0.01). Surviving patients treated with ECMO for PGF have similar conditional 1-year survival rates as non-PGF patients: 93% at 3 years and 91% at 5 years without PGF versus 93% at 3 years and 84% at 5 years with PGF (p = 0.46, NS). Conclusions: Occurrence of PGF is a multifactorial event that depends on both donor and recipient profiles. ECMO support is a reliable treatment for severe PGF;furthermore,survivingpatients treated with ECMO have the same 1-year conditional survival ratesas patients not havingsuffered a PGF. # 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

  • extra corporeal membrane oxygenation temporary support for early graft failure after Cardiac Transplantation
    European Journal of Cardio-Thoracic Surgery, 2009
    Co-Authors: Cosimo Dalessandro, Jeanlouis Golmard, Charlesedouard Luyt, A Pavie, Stephane Aubert, Beltran Levy G Praschker, I Gandjbakhch, Pascal Leprince
    Abstract:

    Objective: Early graft failure (EGF) is a major risk for death after heart Transplantation. We studied the impact of an extra-corporeal membrane oxygenation (ECMO) temporary support on the operative mortality and the mean-term survival after EGF. Materials and methods: Between January 2000 and December 2006, 394 patients underwent orthotopic heart Transplantation at our institution. EGF was observed in 90 (23%) patients. Fifty-four patients (14%) were treated with ECMO support, eight (2%) with other assisting devices, and 28 (7%) received maximal inotropic drug support only. Results: The overall mortality was 21% (83 patients). EGF was a major risk for death: 13% (35 patients) without EGF versus 58% (49 patients) with EGF, p < 0001. Among patients supported with ECMO, 36 (67%) were weaned from the assisting device and 27 (50%) were discharged from the hospital. Overall survival was 73% at 1 year and 66% at 5 years. Absence of EGF improved long-term survival: 78% at 1 year and70% at5 years withoutEGFversus 37%at 1 year and35% at5 years withEGF. Patientstreated withECMO havethe same1-yearconditional survival as patients not having suffered EGF: 94% at 3 years. Conclusions: ECMO support is a reliable therapeutic option in severe EGF after Cardiac Transplantation; furthermore, patients treated with ECMO have the same 1-year conditional survival as patients not having suffered EGF. # 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Jeanlouis Golmard - One of the best experts on this subject based on the ideXlab platform.

  • predictive risk factors for primary graft failure requiring temporary extra corporeal membrane oxygenation support after Cardiac Transplantation in adults
    European Journal of Cardio-Thoracic Surgery, 2011
    Co-Authors: Cosimo Dalessandro, Jeanlouis Golmard, Eleodoro Barreda, M Laali, Ralouka Makris, Charlesedouard Luyt, Pascal Leprince, A Pavie
    Abstract:

    Objective:Primarygraftfailure(PGF)isa majorriskfactorfordeathafterheartTransplantation.Weinvestigatedthepredictiveriskfactorsfor severe PGF that require extra-corporeal membrane oxygenation (ECMO) circulatory support after Cardiac Transplantation. Methods: Between January 2003 and December 2008, 402 adult patients underwent isolated Cardiac Transplantation at our institution. PGF was defined as the need for ECMO support in the immediate postoperative period. Thirty-three recipient and 37 donor variables were analyzed for the risk of PGF occurrence. Results: PGF occurred in 91 (23%) patients. Predictive risk factors for PGF occurrence were, in the recipient, being aged >60 years (odds ratio (OR) 2.11, p = 0.01) and preoperative mechanical circulatory support (MCS) (OR 2.65, p = 0.01); in the donor, they were mean norepinephrine dose (OR 2.02,p < 0.01), trauma as the cause of death(OR 2.45,p < 0.01), left-ventricle ejection fraction (LVEF) <55% (OR 2.72, p = 0.02), and the ischemic time (OR 1.01, p < 0.01). Weaning and discharge rates after ECMO support for PGF were, respectively, 60% (55/91 patients) and 46% (42/91 patients).The absence of PGF was correlated with improved long-termsurvival: 78% at 1 year and 71% at 5 years without PGF versus 39% at 1 year and 34% at 5 years with PGF (p < 0.01). Surviving patients treated with ECMO for PGF have similar conditional 1-year survival rates as non-PGF patients: 93% at 3 years and 91% at 5 years without PGF versus 93% at 3 years and 84% at 5 years with PGF (p = 0.46, NS). Conclusions: Occurrence of PGF is a multifactorial event that depends on both donor and recipient profiles. ECMO support is a reliable treatment for severe PGF;furthermore,survivingpatients treated with ECMO have the same 1-year conditional survival ratesas patients not havingsuffered a PGF. # 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

  • extra corporeal membrane oxygenation temporary support for early graft failure after Cardiac Transplantation
    European Journal of Cardio-Thoracic Surgery, 2009
    Co-Authors: Cosimo Dalessandro, Jeanlouis Golmard, Charlesedouard Luyt, A Pavie, Stephane Aubert, Beltran Levy G Praschker, I Gandjbakhch, Pascal Leprince
    Abstract:

    Objective: Early graft failure (EGF) is a major risk for death after heart Transplantation. We studied the impact of an extra-corporeal membrane oxygenation (ECMO) temporary support on the operative mortality and the mean-term survival after EGF. Materials and methods: Between January 2000 and December 2006, 394 patients underwent orthotopic heart Transplantation at our institution. EGF was observed in 90 (23%) patients. Fifty-four patients (14%) were treated with ECMO support, eight (2%) with other assisting devices, and 28 (7%) received maximal inotropic drug support only. Results: The overall mortality was 21% (83 patients). EGF was a major risk for death: 13% (35 patients) without EGF versus 58% (49 patients) with EGF, p < 0001. Among patients supported with ECMO, 36 (67%) were weaned from the assisting device and 27 (50%) were discharged from the hospital. Overall survival was 73% at 1 year and 66% at 5 years. Absence of EGF improved long-term survival: 78% at 1 year and70% at5 years withoutEGFversus 37%at 1 year and35% at5 years withEGF. Patientstreated withECMO havethe same1-yearconditional survival as patients not having suffered EGF: 94% at 3 years. Conclusions: ECMO support is a reliable therapeutic option in severe EGF after Cardiac Transplantation; furthermore, patients treated with ECMO have the same 1-year conditional survival as patients not having suffered EGF. # 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Charlesedouard Luyt - One of the best experts on this subject based on the ideXlab platform.

  • predictive risk factors for primary graft failure requiring temporary extra corporeal membrane oxygenation support after Cardiac Transplantation in adults
    European Journal of Cardio-Thoracic Surgery, 2011
    Co-Authors: Cosimo Dalessandro, Jeanlouis Golmard, Eleodoro Barreda, M Laali, Ralouka Makris, Charlesedouard Luyt, Pascal Leprince, A Pavie
    Abstract:

    Objective:Primarygraftfailure(PGF)isa majorriskfactorfordeathafterheartTransplantation.Weinvestigatedthepredictiveriskfactorsfor severe PGF that require extra-corporeal membrane oxygenation (ECMO) circulatory support after Cardiac Transplantation. Methods: Between January 2003 and December 2008, 402 adult patients underwent isolated Cardiac Transplantation at our institution. PGF was defined as the need for ECMO support in the immediate postoperative period. Thirty-three recipient and 37 donor variables were analyzed for the risk of PGF occurrence. Results: PGF occurred in 91 (23%) patients. Predictive risk factors for PGF occurrence were, in the recipient, being aged >60 years (odds ratio (OR) 2.11, p = 0.01) and preoperative mechanical circulatory support (MCS) (OR 2.65, p = 0.01); in the donor, they were mean norepinephrine dose (OR 2.02,p < 0.01), trauma as the cause of death(OR 2.45,p < 0.01), left-ventricle ejection fraction (LVEF) <55% (OR 2.72, p = 0.02), and the ischemic time (OR 1.01, p < 0.01). Weaning and discharge rates after ECMO support for PGF were, respectively, 60% (55/91 patients) and 46% (42/91 patients).The absence of PGF was correlated with improved long-termsurvival: 78% at 1 year and 71% at 5 years without PGF versus 39% at 1 year and 34% at 5 years with PGF (p < 0.01). Surviving patients treated with ECMO for PGF have similar conditional 1-year survival rates as non-PGF patients: 93% at 3 years and 91% at 5 years without PGF versus 93% at 3 years and 84% at 5 years with PGF (p = 0.46, NS). Conclusions: Occurrence of PGF is a multifactorial event that depends on both donor and recipient profiles. ECMO support is a reliable treatment for severe PGF;furthermore,survivingpatients treated with ECMO have the same 1-year conditional survival ratesas patients not havingsuffered a PGF. # 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

  • extra corporeal membrane oxygenation temporary support for early graft failure after Cardiac Transplantation
    European Journal of Cardio-Thoracic Surgery, 2009
    Co-Authors: Cosimo Dalessandro, Jeanlouis Golmard, Charlesedouard Luyt, A Pavie, Stephane Aubert, Beltran Levy G Praschker, I Gandjbakhch, Pascal Leprince
    Abstract:

    Objective: Early graft failure (EGF) is a major risk for death after heart Transplantation. We studied the impact of an extra-corporeal membrane oxygenation (ECMO) temporary support on the operative mortality and the mean-term survival after EGF. Materials and methods: Between January 2000 and December 2006, 394 patients underwent orthotopic heart Transplantation at our institution. EGF was observed in 90 (23%) patients. Fifty-four patients (14%) were treated with ECMO support, eight (2%) with other assisting devices, and 28 (7%) received maximal inotropic drug support only. Results: The overall mortality was 21% (83 patients). EGF was a major risk for death: 13% (35 patients) without EGF versus 58% (49 patients) with EGF, p < 0001. Among patients supported with ECMO, 36 (67%) were weaned from the assisting device and 27 (50%) were discharged from the hospital. Overall survival was 73% at 1 year and 66% at 5 years. Absence of EGF improved long-term survival: 78% at 1 year and70% at5 years withoutEGFversus 37%at 1 year and35% at5 years withEGF. Patientstreated withECMO havethe same1-yearconditional survival as patients not having suffered EGF: 94% at 3 years. Conclusions: ECMO support is a reliable therapeutic option in severe EGF after Cardiac Transplantation; furthermore, patients treated with ECMO have the same 1-year conditional survival as patients not having suffered EGF. # 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.